This article is more than 5 years old. Information may no longer be current.

Vyome Biosciences closes $14 million Series C financing to fund acne treatment

Vyome Biosciences has closed a $14 million Series C financing round, with funding predominantly advancing the clinical development of its lead product VB 1953 and other proprietary products, according to a press release.

VB 1953 will be used in the treatment of antibiotic resident acne in anticipated clinical trials. The FDA recently accepted Vyome’s investigational new drug application for VB1053, and the New Delhi, India-based company will soon initiate clinical studies in the United States, according to the release.

“Vyome is well positioned with a rich pipeline to become a leader in antimicrobial resistance and treatment of skin infections with this new funding round,” Shiladitya Sengupta, PhD, MSc, co-founder of Vyome and assistant professor of medicine at Harvard Medical School, stated in the release.

The financing was led by Perceptive Advisors and Romulus Capital, along with participation from investors including Kalaari Capital, Sabre Partners and Aarin Capital, according to the release.

Reference: www.vyome.in